Ye et al., 2024 - Google Patents

Targeting tau in Alzheimer's disease: from mechanisms to clinical therapy

Ye et al., 2024

View HTML
Document ID
11731093228856297545
Author
Ye J
Wan H
Chen S
Liu G
Publication year
Publication venue
Neural Regeneration Research

External Links

Snippet

Alzheimer's disease is the most prevalent neurodegenerative disease affecting older adults. Primary features of Alzheimer's disease include extracellular aggregation of amyloid-β plaques and the accumulation of neurofibrillary tangles, formed by tau protein, in the cells …
Continue reading at journals.lww.com (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds

Similar Documents

Publication Publication Date Title
Nizynski et al. Amyloidogenesis of Tau protein
Uddin et al. Autophagy and Alzheimer’s disease: from molecular mechanisms to therapeutic implications
Yoshiyama et al. Therapeutic strategies for tau mediated neurodegeneration
Cheng et al. The emerging roles of protein homeostasis‐governing pathways in Alzheimer's disease
Oral et al. Physiological and pathological significance of the molecular cross-talk between autophagy and apoptosis
Serasinghe et al. Mitochondrial fission in human diseases
Wang et al. Peptidyl-prolyl cis/trans isomerase Pin1 and Alzheimer’s disease
Gong et al. Targeting tau protein in Alzheimer’s disease
Wolfe The role of tau in neurodegenerative diseases and its potential as a therapeutic target
Mokhtar et al. The Beta‐Amyloid Protein of Alzheimer’s Disease: Communication Breakdown by Modifying the Neuronal Cytoskeleton
Selkoe Alzheimer disease: mechanistic understanding predicts novel therapies
Li et al. Endoplasmic reticulum dysfunction in Alzheimer’s disease
Triaca et al. NGF controls APP cleavage by downregulating APP phosphorylation at Thr668: relevance for Alzheimer's disease
Chang et al. Untangling the Tauopathy for Alzheimer’s disease and parkinsonism
Ye et al. Targeting tau in Alzheimer's disease: from mechanisms to clinical therapy
Wang et al. Delta-secretase phosphorylation by SRPK2 enhances its enzymatic activity, provoking pathogenesis in Alzheimer’s disease
Oakley et al. Tau filament self-assembly and structure: tau as a therapeutic target
Binukumar et al. Peptide TFP5/TP5 derived from Cdk5 activator P35 provides neuroprotection in the MPTP model of Parkinson’s disease
Coyne et al. mPOS is a novel mitochondrial trigger of cell death–implications for neurodegeneration
Strong et al. Alterations in Tau Metabolism in ALS and ALS-FTSD
Iqbal et al. Recent developments with tau-based drug discovery
Dohm et al. Aggregopathy in neurodegenerative diseases: mechanisms and therapeutic implication
Huang et al. Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity
Lauretti et al. Alzheimer’s disease: Phenotypic approaches using disease models and the targeting of tau protein
Rajah Kumaran et al. Insights into the pathophysiology of Alzheimer’s disease and potential therapeutic targets: A current perspective